The Director of National Intelligence, Tulsi Gabbard, has made public a significant amount of declassified documents revealing U.S. funding for over 120 biological laboratories in more than 30 nations. Gabbard asserts that these records validate concerns previously labeled as misinformation.
This disclosure comes after years of backlash against Gabbard, who raised alarms about a U.S.-backed biolab in Ukraine following the Russian invasion in 2022. Some criticized her claims as repeating Russian narratives, while others believed the genuine questions regarding the lab’s operations and oversight were being dismissed without consideration.
The newly released documents include explanatory slides from the Office of the Director of National Intelligence that depict the level of U.S. involvement in Ukraine’s laboratory network.
One notable finding indicates that more than 40 U.S.-funded labs in Ukraine contained collections of hazardous bacteria and viruses, some of which date back to the Soviet era. The records also reveal that Ukrainian scientists were trained with U.S. funding to manage these dangerous pathogens and were involved in programs specifically targeting various serious diseases.
The documents detail the types of pathogens studied in these labs, which include anthrax, tuberculosis, plague, and various deadly viruses. Furthermore, they outline U.S. expenditures on constructing and renovating labs across Ukraine, pinpointing contractor Black & Veatch and indicating that American taxpayers allocated between $1.7 million and $3.5 million per laboratory project.
Additional assessments spotlight the Institute of Veterinary Medicine in Kharkiv, which received financial support from the Department of Defense’s Biological Threat Reduction Program. This facility reportedly harbored numerous samples of perilous pathogens, such as Brucella, which is linked to brucellosis. The document cautions that the institute could fall victim to Russian propaganda campaigns or might be compromised during armed conflict.
Another aspect of the declassification reveals connections between Ukrainian labs and U.S. government entities, research institutions, and private contractors. The funding has been associated with research into avian flu and other highly infections viruses in secure laboratories.
Gabbard points out that these documents demonstrate a lack of transparency about the extent of U.S.-supported biological research overseas. However, detractors maintain that these laboratories are not involved in bioweapons development but are instead part of a broader public health initiative aimed at safeguarding dangerous pathogens and preventing them from spreading.
The release of these records is likely to reignite discussions surrounding government transparency, gain-of-function research, and the broader implications of U.S.-funded biological research abroad.
